The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD
A simple scoring system accurately separates patients with nonalcoholic fatty liver disease with and without advanced fibrosis, rendering liver biopsy for identification ofAdvanced fibrosis unnecessary in a substantial proportion of patients.
Telaprevir for previously untreated chronic hepatitis C virus infection.
- I. Jacobson, J. McHutchison, S. Zeuzem
- MedicineNew England Journal of Medicine
- 22 June 2011
Telaprevir with peginterferon-ribavirin was associated with significantly improved rates of sustained virologic response in patients with HCV genotype 1 infection who had not received previous treatment, with only 24 weeks of therapy administered in the majority of patients.
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
- V. Suppiah, M. Moldovan, J. George
- Biology, MedicineNature Genetics
- 1 October 2009
The data suggest that host genetics may be useful for the prediction of drug response, and they also support the investigation of the role of IL28B in the treatment of HCV and in other diseases treated with IFN-α.
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
- Z. Younossi, Q. Anstee, E. Bugianesi
- MedicineNature reviews: Gastroenterology & hepatology
- 2018
The large number of patients with NAFLD with potential for progressive liver disease creates challenges for screening, as the diagnosis of NASH necessitates invasive liver biopsy.
A new definition for metabolic associated fatty liver disease: an international expert consensus statement.
- M. Eslam, P. Newsome, J. George
- MedicineJournal of Hepatology
- 8 April 2020
NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome
- S. Chitturi, S. Abeygunasekera, J. George
- MedicineHepatology
- 1 February 2002
There is a near‐universal association between NASH and IR irrespective of obesity, and most patients with NASH have IRS, according to the homeostasis model assessment.
Animal models of nonalcoholic fatty liver disease
- L. Hebbard, J. George
- MedicineNature Reviews Gastroenterology &Hepatology
- 2011
This Review discusses the prevalent dietary and inflammation-based genetic animal models described in recent years that have been undertaken using animals to model human steatosis and NAFLD to NASH disease progression.
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
- Z. Younossi, F. Tacke, M. Vos
- MedicineHepatology
- 1 June 2019
To examine the state of NAFLD among different regions and understand the global trajectory of this disease, an international group of experts came together during the 2017 American Association for the Study of Liver Diseases GlobalNAFLD Forum.
Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis
- G. Musso, R. Gambino, M. Cassader
- MedicinePLoS Medicine
- 1 July 2014
In a systematic review and meta-analysis, Giovanni Musso and colleagues examine the association between non-alcoholic fatty liver disease and chronic kidney disease and finds no clear link between the two.
Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection.
- L. Adams, M. Bulsara, G. Jeffrey
- MedicineClinical Chemistry
- 1 October 2005
A model of 4 serum markers plus age and sex provides clinically useful information regarding different fibrosis stages among hepatitis C patients.
...
...